Daiwa Securities Group Inc. Bio Atla, Inc. Transaction History
Daiwa Securities Group Inc.
- $21.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding BCAB
# of Institutions
65Shares Held
17.4MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$1.22 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$1.16 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$867,2150.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$854,7600.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$402,0740.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $16.7M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...